Latest from Jessica Merrill
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.
Politics and policy may get as much attention as deals at the J.P. Morgan Healthcare conference, as this year’s meeting comes just before the inauguration of Donald Trump as US president.
The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).
BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
The company updated investors on its 2025 financial guidance and a recent meeting with incoming US president Trump and HHS secretary nominee Robert F. Kennedy, Jr.